- Home
- FMC vs VKTX Comparison
FMC vs VKTX Comparison
Compare FMC & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMC
- VKTX
- Stock Information
- Founded
- FMC 1910
- VKTX 2012
- Country
- FMC United States
- VKTX United States
- Employees
- FMC N/A
- VKTX N/A
- Industry
- FMC Major Chemicals
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- FMC Industrials
- VKTX Health Care
- Exchange
- FMC Nasdaq
- VKTX Nasdaq
- Market Cap
- FMC 4.6B
- VKTX 3.8B
- IPO Year
- FMC N/A
- VKTX 2015
- Fundamental
- Price
- FMC $13.90
- VKTX $39.42
- Analyst Decision
- FMC Buy
- VKTX Strong Buy
- Analyst Count
- FMC 12
- VKTX 14
- Target Price
- FMC $26.91
- VKTX $87.07
- AVG Volume (30 Days)
- FMC 7.6M
- VKTX 4.6M
- Earning Date
- FMC 10-29-2025
- VKTX 10-22-2025
- Dividend Yield
- FMC 16.69%
- VKTX N/A
- EPS Growth
- FMC N/A
- VKTX N/A
- EPS
- FMC N/A
- VKTX N/A
- Revenue
- FMC $3,608,400,000.00
- VKTX N/A
- Revenue This Year
- FMC N/A
- VKTX N/A
- Revenue Next Year
- FMC $3.27
- VKTX N/A
- P/E Ratio
- FMC N/A
- VKTX N/A
- Revenue Growth
- FMC N/A
- VKTX N/A
- 52 Week Low
- FMC $12.87
- VKTX $18.92
- 52 Week High
- FMC $61.26
- VKTX $56.25
- Technical
- Relative Strength Index (RSI)
- FMC 17.02
- VKTX 62.32
- Support Level
- FMC $12.87
- VKTX $34.67
- Resistance Level
- FMC $14.31
- VKTX $43.15
- Average True Range (ATR)
- FMC 1.13
- VKTX 2.67
- MACD
- FMC -0.17
- VKTX 0.16
- Stochastic Oscillator
- FMC 5.64
- VKTX 58.26
About FMC FMC Corporation
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.